Table 1 Baseline characteristics stratified by the occurrence of CV events
|  | Overall (n = 9154) | Without CV events (n = 8830) | CV events (n = 324) | P value |
|---|---|---|---|---|
TyG index | 8.92 ± 0.56 | 8.92 ± 0.56 | 9.02 ± 0.60 | 0.002 |
TG/HDL-C ratio | 3.83 ± 2.46 | 3.83 ± 2.46 | 3.94 ± 2.53 | 0.432 |
METS-IR | 41.68 ± 7.02 | 41.69 ± 7.01 | 41.57 ± 7.22 | 0.762 |
Age, years | 59.83 ± 9.64 | 59.73 ± 9.62 | 62.66 ± 9.88 | < 0.001 |
Male | 7220 (78.9) | 6975 (79.0) | 245 (75.6) | 0.164 |
BMI, kg/m2 | 25.98 ± 3.16 | 26.00 ± 3.16 | 25.58 ± 3.09 | 0.019 |
Clinical presentation | 0.002 | |||
 CCS | 3582 (39.1) | 3482 (39.4) | 100 (30.9) |  |
 ACS | 5572 (60.9) | 5348 (60.6) | 224 (69.1) |  |
Family history of CAD | 1078 (11.8) | 1034 (11.7) | 44 (13.6) | 0.348 |
Prior MI | 2322 (25.4) | 2210 (25.0) | 112 (34.6) | < 0.001 |
Prior PCI | 2042 (22.3) | 1952 (22.1) | 90 (27.8) | 0.019 |
Prior CABG | 302 (3.3) | 282 (3.2) | 20 (6.2) | 0.005 |
Hypertension | 7681 (83.9) | 7397 (83.8) | 284 (87.7) | 0.073 |
Diabetes | 4202 (45.9) | 4033 (45.7) | 169 (52.2) | 0.025 |
Prior stroke | 1261 (13.8) | 1204 (13.6) | 57 (17.6) | 0.051 |
PAD | 641 (7.0) | 609 (6.9) | 32 (9.9) | 0.051 |
Current smoker | 2880 (31.5) | 2770 (31.4) | 110 (34.0) | 0.357 |
CKD | 143 (1.6) | 134 (1.5) | 9 (2.8) | 0.117 |
SBP, mmHg | 131.33 ± 17.59 | 131.24 ± 17.57 | 133.65 ± 17.90 | 0.016 |
DBP, mmHg | 77.38 ± 10.85 | 77.40 ± 10.83 | 76.91 ± 11.26 | 0.427 |
LVEF, % | 61.85 ± 6.68 | 61.92 ± 6.58 | 59.78 ± 8.76 | < 0.001 |
Laboratory tests | ||||
 Creatinine, μmol/L | 83.41 ± 17.17 | 83.28 ± 16.88 | 87.02 ± 23.33 | < 0.001 |
 eGFR, mL/min/1.73m2 | 85.37 ± 17.50 | 85.53 ± 17.44 | 81.01 ± 18.40 | < 0.001 |
 HbA1c, % | 6.53 ± 1.27 | 6.53 ± 1.26 | 6.78 ± 1.39 | < 0.001 |
 FPG, mmol/L | 6.59 ± 2.42 | 6.56 ± 2.39 | 7.23 ± 3.12 | < 0.001 |
 TG, mmol/L | 1.66 ± 0.81 | 1.66 ± 0.81 | 1.69 ± 0.82 | 0.468 |
 TC, mmol/L | 4.04 ± 1.05 | 4.04 ± 1.05 | 4.02 ± 1.04 | 0.730 |
 HDL-C, mmol/L | 1.10 ± 0.29 | 1.10 ± 0.29 | 1.09 ± 0.29 | 0.595 |
 LDL-C, mmol/L | 2.45 ± 0.91 | 2.46 ± 0.92 | 2.43 ± 0.88 | 0.681 |
 hsCRP, mg/L | 2.63 ± 3.05 | 2.61 ± 3.05 | 3.06 ± 3.21 | < 0.001 |
Procedural data | ||||
 SYNTAX score | 16.45 ± 5.51 | 16.43 ± 5.49 | 17.11 ± 5.91 | 0.028 |
 Left main disease | 1761 (19.2) | 1688 (19.1) | 73 (22.5) | 0.144 |
 Three-vessel disease | 5057 (55.2) | 4870 (55.2) | 187 (57.7) | 0.393 |
 CTO lesion | 1204 (13.2) | 1159 (13.1) | 45 (13.9) | 0.752 |
 Thrombotic lesion | 118 (1.3) | 113 (1.3) | 5 (1.5) | 0.871 |
 Ostial lesion | 1438 (15.7) | 1377 (15.6) | 61 (18.8) | 0.135 |
 Type B2/C lesion | 7222 (78.9) | 6963 (78.9) | 259 (79.9) | 0.690 |
 Severe calcification | 691 (7.5) | 651 (7.4) | 40 (12.3) | 0.001 |
 Number of treated lesions | 1.90 ± 0.81 | 1.90 ± 0.81 | 1.88 ± 0.85 | 0.669 |
 Total stent number | 4.33 ± 2.91 | 4.35 ± 2.93 | 3.96 ± 2.37 | 0.019 |
 Total stent length | 63.69 ± 33.43 | 63.78 ± 33.49 | 61.23 ± 31.86 | 0.178 |
Medications | ||||
 Aspirin | 6775 (74.0) | 6541 (74.1) | 234 (72.2) | 0.495 |
 Clopidogrel | 7693 (84.0) | 7418 (84.0) | 275 (84.9) | 0.733 |
 Statins | 8882 (97.0) | 8568 (97.0) | 314 (96.9) | 1.000 |
 ACEI/ARB | 2378 (26.0) | 2299 (26.0) | 79 (24.4) | 0.547 |
 β blocker | 8185 (89.4) | 7892 (89.4) | 293 (90.4) | 0.607 |
 Antidiabetic drugs | 3227 (35.3) | 3099 (35.1) | 128 (39.5) | 0.116 |